34.08 USD
+0.62 (+1.85%)
At close: Feb 11, 2026
34.08 USD
0 (0%)
After Hours: 2/11/2026, 8:00:02 PM
We assign a fundamental rating of 5 out of 10 to INDV. INDV was compared to 191 industry peers in the Pharmaceuticals industry. INDV has an excellent profitability rating, but there are some minor concerns on its financial health. A decent growth rate in combination with a cheap valuation! Better keep an eye on INDV.
1. Profitability
1.1 Basic Checks
- INDV had positive earnings in the past year.
- INDV had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: INDV reported negative net income in multiple years.
- In multiple years INDV reported negative operating cash flow during the last 5 years.
1.2 Ratios
- INDV's Return On Assets of 8.62% is amongst the best of the industry. INDV outperforms 90.05% of its industry peers.
- The Return On Invested Capital of INDV (50.62%) is better than 100.00% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for INDV is significantly above the industry average of 12.66%.
- The last Return On Invested Capital (50.62%) for INDV is above the 3 year average (43.06%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.62% | ||
| ROE | N/A | ||
| ROIC | 50.62% |
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
1.3 Margins
- INDV has a better Profit Margin (10.34%) than 83.77% of its industry peers.
- INDV's Profit Margin has declined in the last couple of years.
- INDV has a better Operating Margin (24.49%) than 91.62% of its industry peers.
- INDV's Operating Margin has been stable in the last couple of years.
- INDV has a better Gross Margin (85.51%) than 88.48% of its industry peers.
- In the last couple of years the Gross Margin of INDV has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 24.49% | ||
| PM (TTM) | 10.34% | ||
| GM | 85.51% |
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
2. Health
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so INDV is creating value.
- The number of shares outstanding for INDV has been reduced compared to 1 year ago.
- The number of shares outstanding for INDV has been reduced compared to 5 years ago.
- INDV has a worse debt/assets ratio than last year.
2.2 Solvency
- INDV has an Altman-Z score of 2.67. This is not the best score and indicates that INDV is in the grey zone with still only limited risk for bankruptcy at the moment.
- With a decent Altman-Z score value of 2.67, INDV is doing good in the industry, outperforming 65.97% of the companies in the same industry.
- INDV has a debt to FCF ratio of 2.68. This is a good value and a sign of high solvency as INDV would need 2.68 years to pay back of all of its debts.
- INDV has a better Debt to FCF ratio (2.68) than 92.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 2.68 | ||
| Altman-Z | 2.67 |
ROIC/WACC5.26
WACC9.63%
2.3 Liquidity
- INDV has a Current Ratio of 0.96. This is a bad value and indicates that INDV is not financially healthy enough and could expect problems in meeting its short term obligations.
- The Current ratio of INDV (0.96) is worse than 86.39% of its industry peers.
- A Quick Ratio of 0.79 indicates that INDV may have some problems paying its short term obligations.
- The Quick ratio of INDV (0.79) is worse than 82.72% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.96 | ||
| Quick Ratio | 0.79 |
3. Growth
3.1 Past
- The Earnings Per Share has grown by an impressive 256.36% over the past year.
- INDV shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -53.19% yearly.
- The Revenue has decreased by -0.25% in the past year.
- The Revenue has been growing by 8.64% on average over the past years. This is quite good.
EPS 1Y (TTM)256.36%
EPS 3Y-75.32%
EPS 5Y-53.19%
EPS Q2Q%33.33%
Revenue 1Y (TTM)-0.25%
Revenue growth 3Y14.52%
Revenue growth 5Y8.64%
Sales Q2Q%2.28%
3.2 Future
- Based on estimates for the next years, INDV will show a very strong growth in Earnings Per Share. The EPS will grow by 37.61% on average per year.
- Based on estimates for the next years, INDV will show a small growth in Revenue. The Revenue will grow by 1.36% on average per year.
EPS Next Y440.8%
EPS Next 2Y161.63%
EPS Next 3Y95.81%
EPS Next 5Y37.61%
Revenue Next Year3.67%
Revenue Next 2Y-0.17%
Revenue Next 3Y1.6%
Revenue Next 5Y1.36%
3.3 Evolution
- The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 17.39, which indicates a rather expensive current valuation of INDV.
- Based on the Price/Earnings ratio, INDV is valued cheaply inside the industry as 85.34% of the companies are valued more expensively.
- INDV is valuated rather cheaply when we compare the Price/Earnings ratio to 28.23, which is the current average of the S&P500 Index.
- A Price/Forward Earnings ratio of 11.32 indicates a reasonable valuation of INDV.
- Based on the Price/Forward Earnings ratio, INDV is valued cheaply inside the industry as 87.43% of the companies are valued more expensively.
- When comparing the Price/Forward Earnings ratio of INDV to the average of the S&P500 Index (28.01), we can say INDV is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.39 | ||
| Fwd PE | 11.32 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, INDV is valued cheaply inside the industry as 84.29% of the companies are valued more expensively.
- 80.10% of the companies in the same industry are more expensive than INDV, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 35.46 | ||
| EV/EBITDA | 12.87 |
4.3 Compensation for Growth
- INDV's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- INDV has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as INDV's earnings are expected to grow with 95.81% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y161.63%
EPS Next 3Y95.81%
5. Dividend
5.1 Amount
- No dividends for INDV!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
34.08
+0.62 (+1.85%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)10-30 2025-10-30/bmo
Earnings (Next)02-26 2026-02-26/amc
Inst Owners92.33%
Inst Owner Change0.83%
Ins Owners3.78%
Ins Owner Change5.64%
Market Cap4.25B
Revenue(TTM)1.18B
Net Income(TTM)122.00M
Analysts84.62
Price Target46.48 (36.38%)
Short Float %9.74%
Short Ratio4.72
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)81.89%
Min EPS beat(2)71.47%
Max EPS beat(2)92.31%
EPS beat(4)4
Avg EPS beat(4)70.49%
Min EPS beat(4)45.92%
Max EPS beat(4)92.31%
EPS beat(8)6
Avg EPS beat(8)12.14%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)19.31%
Min Revenue beat(2)17.53%
Max Revenue beat(2)21.1%
Revenue beat(4)4
Avg Revenue beat(4)14.97%
Min Revenue beat(4)8.6%
Max Revenue beat(4)21.1%
Revenue beat(8)5
Avg Revenue beat(8)7.48%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)20.38%
PT rev (3m)212.41%
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)0.43%
EPS NY rev (3m)81.51%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)1%
Revenue NY rev (3m)13.87%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 17.39 | ||
| Fwd PE | 11.32 | ||
| P/S | 3.61 | ||
| P/FCF | 35.46 | ||
| P/OCF | 23.64 | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.87 |
EPS(TTM)1.96
EY5.75%
EPS(NY)3.01
Fwd EY8.84%
FCF(TTM)0.96
FCFY2.82%
OCF(TTM)1.44
OCFY4.23%
SpS9.45
BVpS-1.66
TBVpS-1.67
PEG (NY)0.04
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 8.62% | ||
| ROE | N/A | ||
| ROCE | 64.08% | ||
| ROIC | 50.62% | ||
| ROICexc | 3805.17% | ||
| ROICexgc | 5707.75% | ||
| OM | 24.49% | ||
| PM (TTM) | 10.34% | ||
| GM | 85.51% | ||
| FCFM | 10.17% |
ROA(3y)-3.2%
ROA(5y)-1.62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)43.06%
ROIC(5y)30.49%
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)54.5%
ROCE(5y)38.6%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-2.47%
OM growth 5Y-1.25%
PM growth 3Y-81.34%
PM growth 5Y-60.3%
GM growth 3Y0.52%
GM growth 5Y0.74%
F-Score8
Asset Turnover0.83
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | 2.68 | ||
| Debt/EBITDA | 0.97 | ||
| Cap/Depr | 230.77% | ||
| Cap/Sales | 5.08% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 57.14% | ||
| Profit Quality | 98.36% | ||
| Current Ratio | 0.96 | ||
| Quick Ratio | 0.79 | ||
| Altman-Z | 2.67 |
F-Score8
WACC9.63%
ROIC/WACC5.26
Cap/Depr(3y)163.83%
Cap/Depr(5y)132.28%
Cap/Sales(3y)2.67%
Cap/Sales(5y)2.59%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)256.36%
EPS 3Y-75.32%
EPS 5Y-53.19%
EPS Q2Q%33.33%
EPS Next Y440.8%
EPS Next 2Y161.63%
EPS Next 3Y95.81%
EPS Next 5Y37.61%
Revenue 1Y (TTM)-0.25%
Revenue growth 3Y14.52%
Revenue growth 5Y8.64%
Sales Q2Q%2.28%
Revenue Next Year3.67%
Revenue Next 2Y-0.17%
Revenue Next 3Y1.6%
Revenue Next 5Y1.36%
EBIT growth 1Y8.24%
EBIT growth 3Y11.69%
EBIT growth 5Y7.28%
EBIT Next Year1050.98%
EBIT Next 3Y148.27%
EBIT Next 5Y64.69%
FCF growth 1Y236.36%
FCF growth 3Y-74.97%
FCF growth 5Y-48.94%
OCF growth 1Y446.15%
OCF growth 3Y-53.28%
OCF growth 5Y-24.93%
INDIVIOR PHARMACEUTICALS INC / INDV FAQ
What is the fundamental rating for INDV stock?
ChartMill assigns a fundamental rating of 5 / 10 to INDV.
What is the valuation status of INDIVIOR PHARMACEUTICALS INC (INDV) stock?
ChartMill assigns a valuation rating of 8 / 10 to INDIVIOR PHARMACEUTICALS INC (INDV). This can be considered as Undervalued.
What is the profitability of INDV stock?
INDIVIOR PHARMACEUTICALS INC (INDV) has a profitability rating of 7 / 10.
How financially healthy is INDIVIOR PHARMACEUTICALS INC?
The financial health rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 4 / 10.
Is the dividend of INDIVIOR PHARMACEUTICALS INC sustainable?
The dividend rating of INDIVIOR PHARMACEUTICALS INC (INDV) is 0 / 10 and the dividend payout ratio is 0%.